125,053 research outputs found
John Guinn Memoir (1857), transcription, 1941
No full textTypewritten copy of a memoir by John Guinn entitled "Mormon and Indian Wars: The Mountain Meadows Massacre and other Tragedies and Transactions Incident to the Mormon Rebellion of 1857, Together with the Personal Recollections of A Civilian who Witnessed Many of the Thrilling Scenes Described". This copy was excerpted by Charles Kelly from the original, which was acquired from the late Richard B. Shepard of the Shepard\u27s Book Store in Salt Lake City. This copy was made from Charles Kelly\u27s original copy by Dale L. Morgan in September, 1941
Going Beyond Counting First Authors in Author Co-citation Analysis
No full textThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Dispelling the Myths Behind First-author Citation Counts
No full textWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
International progress in cancer gene therapy
No full textWe overview the current status and most recent developments in the field of cancer gene therapy from an international viewpoint. We have largely based our review on presentations from the eigth annual meeting of the International Society for Cell and Gene Therapy of Cancer held in Mumbai, India (www.iscgt.com and www.iscgtindia.com). This has afforded us with the opportunity to describe the most recently published and unpublished data in the field of cancer gene therapy, gaining an insight into the priorities in this field today. In doing so, we hope to have provided a state of the art review of cancer gene therapy, with the help of some of the best-known researchers in the field. In addition, due to the location of the meeting, we had a unique opportunity to listen to some of the seminal cancer gene therapy work being performed in India at this tim
John A. Guinn, Mrs. Code Edwards, Miss Margaret Hudnall
No full textSpecial guests at the Woman\u27s Club public affairs dinner at which President John A. Guinn of Texas State College for Women, right, was guest speaker, were, left to right, Mrs. Code Edwards, president of state TSCW ex-students; Miss Margaret Hudnall, president of the local evening group of TSCW exes; and Mrs. B. K. Tenney, president of the exes luncheon group here.https://mavmatrix.uta.edu/specialcollections_startelegram1950s/15579/thumbnail.jp
Bcl-2 and c-Myc co-operate in the Epstein-Barr virus-immortalised human B-cell line GM607 but do not confer tumourigenicity
No full textEighty-five percent of follicular lymphomas (FL) possess a characteristic t(14;18) translocation that results in the deregulated expression of the proto-oncogene BCL-2. BCL-2 overexpression alone is insufficient for full cellular transformation and at least one other genetic event is believed to be necessary for FL development. Deregulated c-Myc expression has previously been shown to co-operate with Bcl-2 to transform murine fibroblast cell lines and lead to tumor development in mice. We have developed a human model system to study early transformation in lymphoid cells using immortalised lymphoblastoid cells. We sequentially introduced BCL-2 and c-MYC, two proto-oncogenes known to be involved in the transformation of B-cells into EBV immortalised human B cells. We show that the c-Myc and Bcl-2 overexpression, together with EBV immortalization were insufficient to cause full cellular transformation as measured by cell proliferation rates, soft agar and tumourigenicity assays. These results show that more than three genetic hits (EBV infection, BCL-2 and c-MYC overexpression) were required for the full cellular transformation of human lymphoblastoid cells. However, subtle changes in cellular proliferation and sensitivity to apoptosis were documented, at non-limiting dilutions. These changes may confer a susceptibility to the modified cells such that they are more susceptible to the acquisition of additional genetic changes and evolve towards a fully transformed state. In addition, the model system developed may be suitable for the identification of further known and novel oncogenic events involved in the full transformation of B-cell
Elevated expression of the leukaemia associated antigen SSX2IP predicts good survival in acute myeloid leukaemia patients who lack detectable cytogenetic rearrangements
No full textGreiner et al have previously described a positive association between elevated leukemia-associated antigen (LAA) expression (RHAMM, G250/CA9, and PRAME) and survival in 116 acute myeloid leukemia (AML) patients by microarray. We have analyzed 312 presentation AML samples using 199 133A chips and 113 Plus2 chips and segregated AML patients based on above- and below-median levels of expression of the LAA synovial sarcoma X breakpoint 2–interacting protein (SSX2IP). Analysis of Kaplan-Meier curves showed an association between elevated SSX2IP expression and improved survival times (log-rank test, P = .05). We found that SSX2IP expression did not predict the survival of AML patients who had detectable cytogenetic abnormalities; however, it was significantly associated with improved survival rates in patients with no detectable cytogenetic rearrangements (log-rank test, n = 180; P = .007). We also found a correlation between elevated SSX2IP expression and other clinical parameters that are considered to be good prognostic markers: days in remission (log-rank test, P = .03), age at diagnosis (< 60 years; t test, P = .003), and FLT3 WT (t test, P = .004). When we examined SSX2IP together with the expression of other LAAs known to be associated with improved survival, we found a significant correlation with SURVIVIN (Pearson correlation, P = 3.97 x 10–5) and RHAMM (Pearson correlation, P = 4.3 x 10–5). Other groups suggested that the expression of distinct LAAs on leukemic blasts may lead to the eradication of residual disease after intensive chemotherapy. RHAMM and Survivin, like SSX2IP, have increased expression in proliferating cells while RHAMM and SSX2IP are both expressed on the surface of malignant cells. There appears to be a small but growing group of LAAs that are coexpressed in AML patients and are associated with improved survival. We examined whether having 1 or more of SSX2IP, Survivin, or RHAMM affected survival in patients with a normal karyotype and found that having expression of none, 1, 2 or all 3 of these LAAs was a significant prognostic indicator (log-rank test, P = .021, respectively). With regard to the presence of cytogenetic abnormalities, these appear to supersede the influence of elevated LAA expression on prognosis.
In summary, we have found that SSX2IP expression at disease presentation predicts good survival in AML patients with no detectable cytogenetic rearrangements. This may, in part, explain why patients with low LAA expression (often the elderly) fail to elicit effective immune responses and tend to have poorer survival. A new phase in cancer-targeted therapy will be particularly difficult, but especially needed, for AML patients whose tumors lack cytogenetic abnormalities and detectable immunogenic LAA expression and whose survival rates are notably reduced<br/
Serologic detection of diffuse large B-cell lymphoma-associated antigens
No full textDiffuse large B-cell lymphoma (DLBCL) accounts for 30-40% of all adult non-Hodgkin's lymphomas, yet the understanding of its underlying genetic abnormalities remains poor. Our present study used the serological analysis of recombinant cDNA expression libraries (SEREX) technique to identify DLBCL-associated antigens. SEREX screening of testis libraries has previously identified cancer-testis antigens (CTAs) that may act as disease-specific targets for immunotherapy. Screening a testis cDNA expression library with serum from a DLBCL patient identified a total of 94 positive clones, representing 28 distinct antigens. Two of these antigens were novel, 8 were previously uncharacterised, and the remainder were proteins of known function. Screening of the antigens with sera from DLBCL (n = 10), acute myeloid leukaemia (AML, n = 10) and chronic myeloid leukaemia (CML, n = 10) patients, alongside normal healthy donor controls (n = 20), revealed that 7 of the antigens were recognised by DLBCL sera but not normal donor sera, whilst 2 of these antigens were also recognised by leukaemic sera. Some of the genes identified here were already known to be transcribed in DLBCL. The mRNA expression of the majority of the remaining antigens was confirmed in DLBCL cell lines using reverse-transcriptase PCR (RT-PCR). Our study identified a number of DLBCL associated antigens that may be suitable as prognostic/diagnostic markers and/or for the immunotherapy of haematologic malignancie
Pragmatic Case Studies as a Source of Unity in Applied Psychology
No full textTo unify or not to unify applied psychology: that is the question. In this article we review pendulum swings in the historical efforts to answer this question—from a comprehensive, positivist, “top-down,” deductive yes between the 1930s and the early 60s, to a postmodern no since then. A rationale and proposal for a limited, “bottom-up,” inductive yes in applied psychology is then presented, employing a case-based paradigm that integrates both positivist and postmodern themes and components. This paradigm is labeled “pragmatic psychology” and, its specific use of case studies, the “Pragmatic Case Study Method” (“PCS Method”). We call for the creation of peer-reviewed journal-databases of pragmatic case studies as a foundational source of unifying applied knowledge in our discipline. As one example, the potential of the PCS Method for unifying different angles of theoretical regard is illustrated in an area of applied psychology, psychotherapy, via the case of Mrs. B. The article then turns to the broader historical and epistemological arguments for the unifying nature of the PCS Method in both applied and basic psychology.Peer reviewe
Immunotherapy of myeloid leukaemias
No full textThe treatment of myeloid leukaemia has progressed in recent years with the advent of donor leukocyte infusions (DLI), haemopoietic stem cell transplants (HSCTs) and targeted therapies. However, relapse has a high associated morbidity rate and a method for removing diseased cells in first remission, when a minimal residual disease state is achieved and tumour load is low, has the potential to extend remission times and prevent relapse especially when used in combination with conventional treatments. Acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) are heterogeneous diseases which lack one common molecular target while chronic myeloid leukaemia (CML) patients have experienced prolonged remissions through the use of targeted therapies which remove BCR-ABL(+) cells effectively in early chronic phase. However, escape mutants have arisen and this therapy has little effectivity in the late chronic phase. Here we review the immune therapies which are close to or in clinical trials for the myeloid leukaemias and describe their potential advantages and disadvantage
- …
